Thromb Haemost 1997; 77(04): 675-678
DOI: 10.1055/s-0038-1656032
Coagulation
Schattauer GmbH Stuttgart

Decrease in Factor VII Coagulant Activity during Percutaneous Transluminal Coronary Angioplasty by Heparin-Mediated Lipolytic Action

Manjari Mukherjee
1   The Thrombosis Research Institute, Emmanuel Kaye Building, Chelsea, London
,
Michael F Scully
1   The Thrombosis Research Institute, Emmanuel Kaye Building, Chelsea, London
,
Vijay V Kakkar
1   The Thrombosis Research Institute, Emmanuel Kaye Building, Chelsea, London
2   King’s College School of Medicine and Dentistry, London
3   Royal Brompton Hospital, London
,
Helen Philippou
4   Department of Haematology, Charing Cross and Westminster Hospital Medical School, London, UK
,
David A Lane
4   Department of Haematology, Charing Cross and Westminster Hospital Medical School, London, UK
,
David Jewitt
2   King’s College School of Medicine and Dentistry, London
› Author Affiliations
Further Information

Publication History

Received 02 August 1996

Accepted after resubmission 03 December 1996

Publication Date:
11 July 2018 (online)

Summary

Levels of factor VII coagulant activity (FVII: C) and two-chain factor Vila antigen (FVIIa: Ag) were measured in ten patients before and up to 6 h after receiving a bolus of heparin during percutaneous transluminal coronary angioplasty (PTCA). A significant and sustained post-heparin fall in the level of FVII: C was observed (approximately 30%) without any change in the level of FVIIa: Ag. The level of tissue factor antigen within the circulation remained unchanged. The observed decrease in FVII: C coincided with a significant decrease in triglyceride levels presumably due to lipoprotein and hepatic lipase released by the heparin. These findings appear to demonstrate a lipid (triglyceride) dependence of FVII: C. Thus, heparin may act indirectly as antithrombotic agent by limiting a lipid-dependent activation of the extrinsic pathway of coagulation.

 
  • References

  • 1 Meade TW, Mellows S, Brozovic M. et al. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study. Lancet 1986; 02: 5337
  • 2 Meade TW, Wilkes HC, Stirling Y, Brennan PJ, Kelleker C, Browne W. Randomized controlled trial of low dose warfarin in the primary prevention of ischaemic heart disease in men at high risk: design and pilot study. Europ Heart J 1988; 09: 836-843
  • 3 Meade TW, Miller GJ. Combined use of aspirin and warfarin in primary prevention of ischemic heart disease in men at high risk. Am J Cardiol 1995; 75: 23B-26B
  • 4 Morrissey JH. Tissue factor modulation of factor Vila activity: Use in measuring trace levels of factor Vila in plasma. Thromb Haemost 1995; 74: 185-188
  • 5 Seligsohn U, Kaspar CK, Osterud B, Rapaport SI. Activated factor VII: Presence in factor IX concentration and resistance in the circulation after infusion. Blood 1978; 53: 828-833
  • 6 Lawson JH, Butenas S, Ribarik N, Mann KG. Complex-dependent inhibition of factor Vila by antithrombin and heparin. J Biol Chem 1993; 268: 767-770
  • 7 Rao LVM, Rapaport SI, Hoang AD. Binding of factor Vila to tissue factor permits rapid antithrombin Ill/heparin inhibition of factor Vila. Blood 1993; 81: 2600-2607
  • 8 Phillipou H, Adami A, Amersey RA, Stubb PJ, Lane DA. A novel specific immunoassay for plasma two chain factor Vila: investigation of FVIIa levels in normal individuals and in patients with acute coronary syndromes. Blood. 1997 in press.
  • 9 Sandset PM, Abildgaard U, Larsen ML. Heparin induced release of extrinsic pathway inhibitor (EPI). Thromb Res 1988; 50: 803-813
  • 10 Watson TD, Burns L, Packard CJ, Shepherd J. Selective measurement of lipoprotein lipase and hepatic triglyceride lipase in heparinised plasma from horses. Am J Vet Res 1992; 53: 771-775
  • 11 Bengtsson-Olivecrona G, Olivecrona T. Assay of lipoprotein lipase and hepatic lipase. In: Lipoprotein Analysis. A Practical Approach. CA Converse, ER Skinner. (eds). Oxford University Press: 1992. pp 169-185
  • 12 Friedwald WT, Levy RI, Fredrickson D. Estimation of the concentration of low density lipoprotein cholesterol in plasma without the use of preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
  • 13 Warshawsky I, Broze GJ, Schwartz AL. The low density lipoprotein receptor-related protein mediates the cellular degradation of tissue factor pathway inhibitor. Proc Natl Acad Sci USA 1994; 91: 6664-6669
  • 14 Negri M, Arigliano PL, Talamini G, Carlini S, Manzato F, Bonadonna G. Levels of plasma factor VII and factor VII activated forms as a function of plasma triglyceride levels. Atherosclerosis 1993; 99: 55-61
  • 15 Dalaker K, Hjermann I, Prydz H. A novel form of factor VII in plasma from men at risk for cardiovascular disease. Brit J Haematol 1985; 61: 315-322
  • 16 Dalaker K, Smith P, Amerson H, Prydz H. Factor VH-phospholipid complex in male survivors of acute myocardial infarction. Acta Med Scand 1987; 222: 111-116
  • 17 Giercksky K-E. The procoagulant activity of adipose tissue. Scand J Haemotol 1977; 19: 385-395
  • 18 Lino M, Kisiel W. Sphingosine-containing phopholipid vesicles support human factor VII autoactivation in the absence of tissue factor. Thromb Res 1996; 82: 119-127
  • 19 Mukherjee M, Dawson G, Sembhi K, Kakkar VV. Triglyceride dependence of factor VII coagulant activity in deep venous thrombosis. Thromb Haemost 1996; 76: 500-501
  • 20 Avellone G, DiGarbo V, Cordova R, Piliego T, Raneli G, DiSimone R, Bompiani GD. Improvement of fibrinolysis and plasma lipoprotein levels induced by gemfibrozil in hypertriglyceridemia. Blood Coag Fibrinol 1995; 06: 543-548